Skip to main content
Veterinary Medicines

HISTABIOSONE

Authorised
  • Dexamethasone
  • Chlorphenamine maleate
  • Benzylpenicillin procaine monohydrate
  • Dihydrostreptomycin sulfate

Product identification

Medicine name:
HISTABIOSONE
Active substance:
  • Dexamethasone
  • Chlorphenamine maleate
  • Benzylpenicillin procaine monohydrate
  • Dihydrostreptomycin sulfate
Target species:
  • Cattle
  • Pig
  • Goat
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Dexamethasone
    0.50
    milligram(s)
    /
    1.00
    millilitre(s)
  • Chlorphenamine maleate
    10.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Benzylpenicillin procaine monohydrate
    200.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Dihydrostreptomycin sulfate
    312.90
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        30
        day
      • Milk
        5
        day
    • Pig
      • Meat and offal
        30
        day
    • Goat
      • Milk
        5
        day
      • Meat and offal
        30
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01RV01
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet
Marketing authorisation date:
Manufacturing sites for batch release:
  • Trirx Segre
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/7978797 4/1988
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 4/04/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."